Celator® Pharmaceuticals Presents Data on CPX-351 at the 56th American Society of Hematology Annual Meeting
PR Newswire - Wed Dec 10, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data on its lead product candidate, CPX-351 (cytarabine:daunorubicin) Liposome for Injection, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, held December 6-9, 2014.
CPXX: 1.95 (unch)
Celator® Pharmaceuticals Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351
PR Newswire - Mon Dec 01, 7:30AM CST
EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML), has completed a planned safety review and recommended that the study continue as planned without any modifications.
CPXX: 1.95 (unch)
Celator® Pharmaceuticals to Present Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Mon Nov 24, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014.
CPXX: 1.95 (unch)
Celator Pharmaceuticals' (CPXX) CEO Scott Jackson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 2:02PM CST
CPXX: 1.95 (unch)
Celator Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:22PM CST
CPXX: 1.95 (unch)
Celator® Pharmaceuticals Announces Business Update And Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the third quarter ended September 30, 2014.
CPXX: 1.95 (unch)
Celator® Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Stifel 2014 Healthcare Conference on November 19, 2014 at 4:10 p.m. ET in New York City.
CPXX: 1.95 (unch)
Celator Pharma reports November 13
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 12:13PM CST
CPXX: 1.95 (unch)
Celator® Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 13, 2014
PR Newswire - Tue Nov 04, 11:20AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Thursday, November 13, 2014, at 4:30 p.m. ET to report third quarter 2014 financial results.
CPXX: 1.95 (unch)
Celator(R) Pharmaceuticals to Present on Liposome Delivery Systems at 2014 American Association of Pharmaceutical Scientists Annual Meeting
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Dr. Lawrence Mayer, President, Founder and Chief Scientific Officer of Celator, will present at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego, California on Wednesday, November 5, 2014, as part of the Advances in Lipid-Based Delivery Systems for Transdermal, Oral, and Parenteral Administered Drugs session. Dr. Mayer's presentation is scheduled at 2:50 p.m. PST/5:50 p.m. EST.
CPXX: 1.95 (unch)
Celator(R) Pharmaceuticals Announces Completion of Its Public Offering and the Exercise in Full of Option to Purchase Additional Units of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Tue Oct 28, 9:49AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the closing of an underwritten public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock, including the exercise in full of the underwriters' over-allotment option to purchase up to an additional 991,673 units. The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The shares of common stock and the warrants are immediately separable and were issued separately. The warrants have an exercise price of $3.58 per whole share and have a term of five years. The net proceeds to Celator, after underwriting discounts and commissions and estimated offering expenses, were approximately $13.5 million.
CPXX: 1.95 (unch)
Celator(R) Pharmaceuticals Announces Phase 3 Clinical Study of CPX-351 Achieved Target Enrollment in High Risk (Secondary) Acute Myeloid Leukemia
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the target enrollment of 300 patients has been achieved in the company's multicenter, randomized, open-label Phase 3 study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the current standard of care, conventional cytarabine and daunorubicin therapy (7+3) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML). The study randomized the 300 patient ahead of schedule and will remain open for a short time to enable all patients currently in the process of referral and evaluation to complete enrollment into the study.
CPXX: 1.95 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 11:45AM CDT
IHT: 2.12 (unch), AIRM: 42.29 (-0.34), MGT: 0.71 (+0.02), NCT: 4.96 (-0.07), BBW: 20.57 (-0.11), ADHD: 3.41 (+0.16), CAB: 48.99 (-0.27), IPCM: 43.63 (-0.18), VII: 1.44 (unch), MTRN: 33.46 (-1.25), UTEK: 17.71 (+0.08), CPXX: 1.95 (unch), BRP: 23.01 (-0.33), SHLM: 37.32 (-0.90), NPTN: 3.13 (-0.03), IBIO: 0.69 (unch), YELP: 52.70 (+0.25), CLRO: 9.63 (-0.33), VPCO: 1.31 (+0.04), INFN: 14.05 (+0.05)
Celator(R) Pharmaceuticals Announces Pricing of a $12.9 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the pricing of an underwritten public offering of 6,611,150 shares of common stock and warrants to purchase up to 661,115 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The gross proceeds to Celator from this offering are expected to be approximately $12.9 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company and exclusive of any warrant exercises. The shares of common stock and the warrants are immediately separable and will be issued separately. The warrants will be exercisable upon issuance at an exercise price of $3.58 per whole share and will have a term of five years. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 991,673 units to cover over-allotments, if any. The offering is expected to close on or about October 28, 2014, subject to customary closing conditions.
CPXX: 1.95 (unch)
Celator Pharmaceuticals to issue public offering of units
M2 - Mon Oct 20, 6:33AM CDT
Pharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) said on Friday that it plans to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
CPXX: 1.95 (unch)
Celator(R) Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Fri Oct 17, 11:58AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock. Roth Capital Partners and National Securities Corporation are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CPXX: 1.95 (unch)
Celator(R) Pharmaceuticals to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference
GlobeNewswire - Fri Sep 19, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at BioCentury's 21 Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 3:30 p.m. ET in New York City.
CPXX: 1.95 (unch)
Celator(R) Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on September 17, 2014
GlobeNewswire - Wed Sep 17, 8:27AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Celator team, led by Scott Jackson, Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell this afternoon. The ceremony is in recognition of the company listing on NASDAQ within the past year and to celebrate recent successes, including the development progress made with lead compound, CPX-351, and the decision to broaden potential clinical applications of the Company's proprietary CombiPlex(R) technology platform.
CPXX: 1.95 (unch)
Celator Pharmaceuticals Inc. (NASDAQ: CPXX) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Tue Sep 16, 9:06AM CDT
What:
CPXX: 1.95 (unch), NDAQ: 46.11 (-0.86)
Celator(R) Pharmaceuticals Announces Publication of Preclinical Data for CPX-351 in Acute Lymphoblastic Leukemia Models
GlobeNewswire - Mon Sep 15, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the publication of preclinical data in Pediatric Blood & Cancer that further characterize the therapeutic potential of lead compound CPX-351 in hematological malignancies and support its ongoing clinical testing in pediatric patients with ALL. CPX-351 is currently being studied in a pivotal Phase 3 clinical trial in older patients with high risk (secondary) AML.
CPXX: 1.95 (unch)